ROBERTS BRYAN E
Known title: DirectorCIK: 0001239242
Associated companies
Transaction History
| TXG | ▲ Buy | Grant | 1,865 | $0 | 6/14/2023 | View on chart |
| TXG | ▼ Sell | Other | 3,790,422 | $0 | 5/17/2023 | View on chart |
| TXG | ▲ Buy | Grant | 2,120 | $0 | 6/15/2022 | View on chart |
| TXG | ▲ Buy | Grant | 1,865 | $0 | 6/14/2023 | View on chart |
| TXG | ▼ Sell | Other | 3,790,422 | $0 | 5/17/2023 | View on chart |
| TXG | ▲ Buy | Grant | 2,120 | $0 | 6/15/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
10x Genomics Partners With Fred Hutchinson Cancer Center
10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.
10x Genomics Partners With Fred Hutchinson Cancer Center. 10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.